Array BioPharma Competitors and Similar CompaniesClear all
Array BioPharma's competitors and similar companies include Avid Bioservices, Amicus Therapeutics, NIOX and Durect.
 Array BioPharma Array BioPharma is focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. |  Avid Bioservices Avid Bioservices, formerly Peregrine Pharmaceuticals, is a biopharmaceutical company. |  Amicus Therapeutics Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases. |  NIOX NIOX (formerly Circassia) is a specialty biopharmaceutical company focused on developing novel immunotherapies |  Durect DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases. | |
Founding Date | Founding Date 1998 | Founding Date 1981 | Founding Date 2002 | Founding Date 2006 | Founding Date N/A |
Type | Type Subsidiary | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Boulder, US HQ Chicago, US Detroit, US Houston, US Miami, US New York, US Phoenix, US | Locations Tustin, US HQ | Locations Philadelphia, US HQ Northbridge, AU Pointe Claire, CA Paris, FR München, DE Dublin, IE Milano, IT see more | Locations Morrisville, US HQ Bad Homburg Vor Der Höhe, DE Uppsala, SE Morrisville, US | Locations Cupertino, US HQ |
Employees | Employees 110 | Employees 21114% increase | Employees 58415% increase | Employees 91 | Employees 902% increase |
Valuation ($) | Valuation ($) N/A | Valuation ($) 649.4 m | Valuation ($) 3.4 b | Valuation ($) 340.9 m | Valuation ($) 45.3 m |
Financial | |||||
Revenue (est.) | Revenue (est.) $173.8m (FY, 2018) | Revenue (est.) $139.9m (FY, 2024) | Revenue (est.) $634.2m (FY, 2025) | Revenue (est.) £48.7m (FY, 2025) | Revenue (est.) $2m (FY, 2024) |
Cost of goods | Cost of goods $59.4m (FY, 2018) | Cost of goods $132.6m (FY, 2024) | Cost of goods $72.9m (FY, 2025) | Cost of goods £11.1m (FY, 2025) | Cost of goods $78k (FY, 2024) |
Gross profit | Gross profit $114.4m (FY, 2018) | Gross profit $7.3m (FY, 2024) | Gross profit $561.3m (FY, 2025) | Gross profit £38.2m (FY, 2025) | Gross profit $2m (FY, 2024) |
Net income | Net income ($147.7m) (FY, 2018) | Net income ($140.8m) (FY, 2024) | Net income ($27.1m) (FY, 2025) | Net income £7m (FY, 2025) | Net income ($8.3m) (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 88m | Total funding raised $ 122.8m | Total funding raised $ 20m |
For sources of this data, please see the company profile
View Company Profiles
Avid Bioservices
HQ
Tustin, US
Employees
211↑ 14% increase
Avid Bioservices, formerly Peregrine Pharmaceuticals, is a biopharmaceutical company.
View companyAmicus Therapeutics
HQ
Philadelphia, US
Employees
584↑ 15% increase
Amicus Therapeutics is a biopharmaceutical company developing therapies for the treatment of rare and orphan diseases.
View companyNIOX
HQ
Morrisville, US
Employees
91
NIOX (formerly Circassia) is a specialty biopharmaceutical company focused on developing novel immunotherapies
View companyDurect
HQ
Cupertino, US
Employees
90↑ 2% increase
DURECT is a specialty pharmaceutical company developing innovative drugs for pain and chronic diseases.
View company